{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:52:41Z","timestamp":1790805161870,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005139.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000}}],"reference-count":308,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005139.pub4","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T02:33:45Z","timestamp":1551753225000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Anti-vascular endothelial growth factor for neovascular age-related macular degeneration"],"prefix":"10.1002","volume":"2019","author":[{"given":"Sharon D","family":"Solomon","sequence":"first","affiliation":[{"name":"Johns Hopkins University School of Medicine; Wilmer Eye Institute; 600 North Wolfe Street Maumenee 740 Baltimore Maryland USA 21287"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lindsley","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health; Department of Epidemiology; 615 North Wolfe Street, Mail Room E6132 Baltimore Maryland USA 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyanarayana S","family":"Vedula","sequence":"additional","affiliation":[{"name":"Johns Hopkins University; 3400 N. Charles Street Baltimore Maryland USA 21218"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena G","family":"Krzystolik","sequence":"additional","affiliation":[{"name":"Mass Eye and Ear Infirmary; Department of Ophthalmology, Retina Service; 1 Randall Square, Suite 203 Providence Rhode Island USA 02904"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine; Wilmer Eye Institute; 600 North Wolfe Street Maumenee 740 Baltimore Maryland USA 21287"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1167\/iovs.11-8130","article-title":"Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration","volume":"53","author":"Keane","year":"2012","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1167\/iovs.10-6208","article-title":"Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age-related macular degeneration","volume":"52","author":"Patel","year":"2011","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0003|cit3","first-page":"ARVO E-abstract","article-title":"The ABC trial - a randomized double-masked phase III study of the efficacy and safety of Avastin\u00ae (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age-related macular degeneration (AMD)","volume":"48","author":"Patel","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0004|cit4","first-page":"4794","article-title":"Impact of anti-vascular endothelial growth factor therapy on reading performance in age-related macular degeneration: a randomized controlled trial","volume":"56(7)","author":"Patel","year":"2015","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1745-6215-9-56","article-title":"A randomised, double-masked phase III\/IV study of the efficacy and safety of Avastin\u00ae (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design","volume":"9","author":"Patel","year":"2008","journal-title":"Trials"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"c2459","DOI":"10.1136\/bmj.c2459","article-title":"Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study","volume":"340","author":"Tufail","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0007|cit7","first-page":"ARVO E-abstract","article-title":"Ranibizumab (Lucentis\u00ae) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data","volume":"47","author":"Alexander","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/IAE.0b013e3181dcfb0b","article-title":"Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab","volume":"30","author":"Barbazetto","year":"2010","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ajo.2010.01.007","article-title":"Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials","volume":"149","author":"Barbazetto","year":"2010","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/IAE.0b013e31825db6ba","article-title":"Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials","volume":"32","author":"Bressler","year":"2012","journal-title":"Retina"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/archophthalmol.2008.562","article-title":"Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial","volume":"127","author":"Bressler","year":"2009","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","article-title":"Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR","volume":"117","author":"Bressler","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ophtha.2012.07.027","article-title":"Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab","volume":"120","author":"Bressler","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0014|cit14","unstructured":"Bressler NM Dolan CM Fine J Marceau C Chang TS Vision-specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT European VitreoRetinal Society 2006. Symposium II: Anti-Angiogenesis (Part 2). www.evrs.eu\/2006-evrs-congress-cannes"},{"issue":"14","key":"10.1002\/14651858.CD005139.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0017|cit17","first-page":"ARVO E-abstract","article-title":"Subgroup analysis of first-year results of ANCHOR: a phase III, double-masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age-related macular degeneration","volume":"47","author":"Brown","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0018|cit18","first-page":"ARVO E-abstract","article-title":"Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis\u00ae)","volume":"47","author":"Chang","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0019|cit19","first-page":"ARVO E-Abstract","article-title":"Ranibizumab (Lucentis\u00ae) for neovascular age-related macular degeneration (AMD): 1-year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR","volume":"48","author":"Ciulla","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.ophtha.2011.05.026","article-title":"Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration","volume":"118","author":"Cunningham","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0021|cit21","first-page":"ARVO E-Abstract","article-title":"Time course of visual acuity changes with ranibizumab (Lucentis\u00ae) in the 2-year ANCHOR study of patients with neovascular age-related macular degeneration (AMD)","volume":"48","author":"Heier","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results","volume":"144","author":"Kaiser","year":"2007","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0023|cit23","unstructured":"Korobelnik JF Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). www.evrs.eu\/2006-evrs-congress-cannes"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0024|cit24","first-page":"ARVO E-abstract","article-title":"Ranibizumab and patient-reported outcomes: VFQ-25 data from the ANCHOR and PIER trials in patients with neovascular AMD","volume":"49","author":"Lanzetta","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0025|cit25","unstructured":"Lanzetta P MARINA and ANCHOR Study Groups Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). www.evrs.eu\/2006-evrs-congress-cannes"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0026|cit26","unstructured":"Loewenstein A MARINA and ANCHOR Study Groups Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age-related macular degeneration European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). www.evrs.eu\/2006-evrs-congress-cannes"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0027|cit27","unstructured":"McDonald HR Schneider S Sy JP One-year results of ANCHOR: a phase III, multicenter, randomized, double-masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age-related macular degeneration The Macula Society 2006 114"},{"issue":"11","key":"10.1002\/14651858.CD005139.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0029|cit29","first-page":"ARVO E-abstract","article-title":"Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials","volume":"48","author":"Rosenfeld","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0031|cit31","first-page":"ARVO E-abstract","article-title":"Lesion characteristics in ranibizumab (Lucentis\u00ae) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age-related macular degeneration (AMD)","volume":"49","author":"Rosenfeld","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0032|cit32","first-page":"ARVO E-abstract","article-title":"Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis\u00ae) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age-related macular degeneration (AMD)","volume":"48","author":"Sadda","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/IAE.0b013e3181e44599","article-title":"Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study","volume":"30","author":"Sadda","year":"2010","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0034|cit34","first-page":"ARVO E-abstract","article-title":"Patient-reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT","volume":"48","author":"Schwartz","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0035|cit35","first-page":"ARVO E-abstract","article-title":"Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration: subanalysis of clinical trial data and clinical routine use","volume":"49","author":"Sutter","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0036|cit36","unstructured":"Webster MK Blodi BA Elledge JA Danis RP Angiographic results of the ANCHOR study of ranibizumab in neovascular age-related macular degeneration: reading center evaluation of angiographic data Investigative Ophthalmology and Visual Science 2007 ARVO E-Abstract 4583"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ophtha.2012.11.042","article-title":"Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials","volume":"120","author":"Weinberg","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0038|cit38","first-page":"ARVO E-abstract","article-title":"Self-reported perception of driving function after ranibizumab therapy in patients with neovascular age-related macular degeneration (AMD)","volume":"49","author":"Win","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0040|cit39","first-page":"ARVO E-abstract","article-title":"Visual acuity gain with ranibizumab therapy: two-year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD","volume":"49","author":"Wolf","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0039|cit40","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1136\/bjophthalmol-2011-300471","article-title":"Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR","volume":"95","author":"Wolf","year":"2011","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0041|cit41","first-page":"ARVO E-Abstract","article-title":"Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age-related macular degeneration","volume":"48","author":"Yang","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0301-4738.81023","article-title":"Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration","volume":"59","author":"Biswas","year":"2011","journal-title":"Indian Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"e0153052","DOI":"10.1371\/journal.pone.0153052","article-title":"Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD study","volume":"11","author":"Schauwvlieghe","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0044|cit44","first-page":"870","article-title":"Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration","volume":"55(13)","author":"Schauwvlieghe","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0049|cit45","unstructured":"Comparison of Age-Related Macular Degeneration Treatment Trials www.med.upenn.edu\/cpob\/studies\/documents\/CATTEligibilityCriteria.pdf"},{"issue":"2","key":"10.1002\/14651858.CD005139.pub4-BIB0045|cit46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2014.08.020","article-title":"Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT)","volume":"122","author":"Altaweel","year":"2015","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD005139.pub4-BIB0046|cit47","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1002\/14651858.CD005139.pub4-BIB0047|cit48","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0048|cit49","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.ophtha.2015.02.031","article-title":"Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"122","author":"Ciulla","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2015.10.034","article-title":"Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)","volume":"123","author":"Daniel","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Daniel E Toth CA Grunwald JE Jaffe GJ Martin DF Fine SL Risk of scar in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology 2014 656 66","DOI":"10.1016\/j.ophtha.2013.10.019"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD005139.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ophtha.2012.02.013","article-title":"Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"119","author":"Grunwald","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0054|cit54","first-page":"1649","article-title":"Size and growth of geographic atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)","volume":"55(13)","author":"Grunwald","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of Comparison of Age-related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Hagstrom SA Ying GS Pauer GJ Sturgill-Short GM Huang J Callanan DG Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT) Ophthalmology 2013 593 9","DOI":"10.1016\/j.ophtha.2012.11.037"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0058|cit58","first-page":"657","article-title":"Impact of change in retinal thickness on refractive error in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)","volume":"55(13)","author":"Huang","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0061|cit60","unstructured":"Maguire MG Comparing treatments for age-related macular degeneration: safety, effectiveness and cost LDI Issue Brief 2012 1 4"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0060|cit61","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.ophtha.2013.03.017","article-title":"Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"120","author":"Maguire","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD005139.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ophtha.2014.10.027","article-title":"Postinjection endophthalmitis in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)","volume":"122","author":"Meredith","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0064|cit64","first-page":"1657","article-title":"Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT)","volume":"56(7)","author":"Pistilli","year":"2015","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ophtha.2015.11.030","article-title":"Angiographic cystoid macular edema and outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Shah","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","article-title":"Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"122","author":"Willoughby","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","article-title":"Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatments Trials (CATT)","volume":"122","author":"Ying","year":"2015","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD005139.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0071|cit71","unstructured":"A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation www.ivan-trial.co.uk\/Default.aspx"},{"issue":"8","key":"10.1002\/14651858.CD005139.pub4-BIB0075|cit72","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.ophtha.2012.06.029","article-title":"Erratum: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399-1411))","volume":"119","year":"2012","journal-title":"Ophthalmology"},{"issue":"78","key":"10.1002\/14651858.CD005139.pub4-BIB0072|cit73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19780","article-title":"A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation (IVAN)","volume":"19","author":"Chakravarthy","year":"2015","journal-title":"Health Technology Assessment"},{"issue":"9900","key":"10.1002\/14651858.CD005139.pub4-BIB0073|cit74","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD005139.pub4-BIB0074|cit75","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/bjophthalmol-2015-307595","article-title":"Changes in intraocular pressure in study and fellow eyes in the IVAN trial","volume":"100","author":"Foss","year":"2016","journal-title":"British Journal of Ophthalmology."},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.ophtha.2013.07.046","article-title":"Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN study","volume":"120","author":"Lotery","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin Study treat-and-extend protocol: two-year results","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","article-title":"A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"British Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/IAE.0b013e3181dcfb0b","article-title":"Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab","volume":"30","author":"Barbazetto","year":"2010","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ajo.2010.01.007","article-title":"Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials","volume":"149","author":"Barbazetto","year":"2010","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD005139.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","article-title":"Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration","volume":"114","author":"Boyer","year":"2007","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/IAE.0b013e31825db6ba","article-title":"Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials","volume":"32","author":"Bressler","year":"2012","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ophtha.2009.09.002","article-title":"Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR","volume":"117","author":"Bressler","year":"2010","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ophtha.2012.07.027","article-title":"Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab","volume":"120","author":"Bressler","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0088|cit87","first-page":"ARVO E-Abstract","article-title":"Self-reported perception of driving function following ranibizumab treatment in patients with neovascular AMD","volume":"48","author":"Chang","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"11","key":"10.1002\/14651858.CD005139.pub4-BIB0087|cit88","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/archopht.125.11.1460","article-title":"Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial","volume":"125","author":"Chang","year":"2007","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0089|cit89","unstructured":"Chang TS Fine JT Alexander S Bressler N Ranibizumab (Lucentis \u00ae ) self-reported vision specific quality of life through 12 months in age-related macular degeneration patients with minimally classic or occult-with-no-classic choroidal neovascularization in a phase III randomized clinical trial The Macula Society 2006 106"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0090|cit90","first-page":"ARVO E-abstract","article-title":"Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis\u00ae)","volume":"47","author":"Chang","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0091|cit91","unstructured":"Chang TS Fine JT Dolan CM Marceau C Bressler NM Ranibizumab (Lucentis \u00ae ) vision-specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial European VitreoRetinal Society 2006. Symposium II: Anti-Angiogenesis (Part 2). www.evrs.eu\/2006-evrs-congress-cannes"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0092|cit92","first-page":"ARVO E-abstract","article-title":"Ranibizumab (Lucentis\u00ae) for neovascular age-related macular degeneration (AMD): 1-year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR","volume":"48","author":"Ciulla","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.ophtha.2011.05.026","article-title":"Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration","volume":"118","author":"Cunningham","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0094|cit94","first-page":"ARVO E-abstract","article-title":"Randomized, controlled phase III study of ranibizumab (Lucentis\u00ae) for minimally classic or occult neovascular age-related macular degeneration: two-year efficacy results of the MARINA study","volume":"47","author":"Heier","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0095|cit95","unstructured":"Ho A Shapiro H Acharya N Ranibizumab for neovascular age-related macular degeneration: one-year subanalysis of the MARINA study The Macula Society 2006 108"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0096|cit96","unstructured":"Holekamp NM Acharya N Shapiro H Two-year FA\/OCT results of MARINA study of ranibizumab (Lucentis \u00ae ) in neovascular AMD American Academy of Ophthalmology 2006 194"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1478-7547-6-12","article-title":"Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration","volume":"6","author":"Hurley","year":"2008","journal-title":"Cost Effectiveness and Resource Allocation"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.ophtha.2007.04.030","article-title":"Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration","volume":"114","author":"Kaiser","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0099|cit99","unstructured":"Kokame GT Anatomic outcomes from the MARINA study of ranibizumab (Lucentis \u00ae ) for minimally classic or occult neovascular age-related macular degeneration The Macula Society 2006 110"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0100|cit100","unstructured":"Korobelnik JF Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). www.evrs.eu\/2006-evrs-congress-cannes"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0101|cit101","unstructured":"Lanzetta P MARINA and ANCHOR Study Groups Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). www.evrs.eu\/2006-evrs-congress-cannes"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0102|cit102","unstructured":"Loewenstein A MARINA and ANCHOR Study Groups Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age-related macular degeneration European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). www.evrs.eu\/2006-evrs-congress-cannes"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0103|cit103","first-page":"ARVO E-abstract","article-title":"Randomized, controlled phase III study of ranibizumab (Lucentis\u00ae) for minimally classic or occult neovascular age-related macular degeneration: two-year safety results of the MARINA study","volume":"47","author":"Miller","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0104|cit104","unstructured":"Reichel E Shapiro H Acharya N Subgroup analyses of two-year results of MARINA study of ranibizumab in neovascular AMD American Academy of Ophthalmology 2006 194"},{"issue":"11","key":"10.1002\/14651858.CD005139.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1002\/14651858.CD005139.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0107|cit107","first-page":"ARVO E-abstract","article-title":"Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials","volume":"48","author":"Rosenfeld","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0109|cit109","first-page":"ARVO E-abstract","article-title":"Lesion characteristics in ranibizumab (Lucentis\u00ae) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age-related macular degeneration (AMD)","volume":"49","author":"Rosenfeld","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0110|cit110","unstructured":"Schmidt-Erfurth U Williams GA MARINA Study Group Two-year efficacy and safety results from the MARINA study European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). www.evrs.eu\/2006-evrs-congress-cannes"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0111|cit111","first-page":"ARVO E-Abstract","article-title":"Vision-related function after ranibizumab treatment by better- or worse-seeing eye: 24 month results from MARINA","volume":"48","author":"Suner","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0112|cit112","first-page":"ARVO E-abstract","article-title":"Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration: subanalysis of clinical trial data and clinical routine use","volume":"49","author":"Sutter","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0113|cit113","first-page":"ARVO E-abstract","article-title":"Ranibizumab (Lucentis\u00ae) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data","volume":"47","author":"Webster","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ophtha.2012.11.042","article-title":"Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials","volume":"120","author":"Weinberg","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0116|cit115","first-page":"ARVO E-abstract","article-title":"Visual acuity gain with ranibizumab therapy: two-year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD","volume":"49","author":"Wolf","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0115|cit116","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1136\/bjophthalmol-2011-300471","article-title":"Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR","volume":"95","author":"Wolf","year":"2011","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0117|cit117","first-page":"ARVO E-abstract","article-title":"Relationship between patient-reported visual function and visual acuity in subjects with neovascular AMD","volume":"48","author":"Yu","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0118|cit118","unstructured":"Abraham P Yue H Shams N PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age-related macular degeneration European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). www.evrs.eu\/2006-evrs-congress-cannes"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham","year":"2010","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/IAE.0b013e3181dcfb0b","article-title":"Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab","volume":"30","author":"Barbazetto","year":"2010","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0121|cit121","first-page":"ARVO E-Abstract","article-title":"Ranibizumab for neovascular age-related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study","volume":"49","author":"Benz","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/IAE.0b013e31825db6ba","article-title":"Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials","volume":"32","author":"Bressler","year":"2012","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0123|cit123","unstructured":"Brown DM Chung CY Tuomi L Ranibizumab (Lucentis \u00ae ) for neovascular age-related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study The Macula Society 2008 78"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/IAE.0b013e318263cedf","article-title":"Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration","volume":"33","author":"Brown","year":"2013","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0125|cit125","first-page":"ARVO E-Abstract","article-title":"Ranibizumab (Lucentis\u00ae) in neovascular age-related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data","volume":"48","author":"Brown","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.ophtha.2011.05.026","article-title":"Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration","volume":"118","author":"Cunningham","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0127|cit127","unstructured":"Ho AC Shapiro H Wilson L Ranibizumab (Lucentis \u00ae ) for neovascular age-related macular degeneration (AMD): two-year angiographic results of PIER study The Macula Society 2008 164"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0128|cit128","first-page":"ARVO E-Abstract","article-title":"Ranibizumab in wet age-related macular degeneration (AMD): crossover\/rollover patient results in PIER study","volume":"49","author":"Ho","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0129|cit129","unstructured":"Kaiser PK Yue H Shams N Subgroup analyses of one-year results of the PIER study of ranibizumab in neovascular AMD American Academy of Ophthalmology 2006 195"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0130|cit130","first-page":"ARVO E-Abstract","article-title":"Ranibizumab and patient-reported outcomes: VFQ-25 data from the ANCHOR and PIER trials in patients with neovascular AMD","volume":"49","author":"Lanzetta","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0131|cit131","first-page":"ARVO E-Abstract","article-title":"Ranibizumab (Lucentis\u00ae) for neovascular age-related macular degeneration (AMD): 2-year angiographic results of PIER study","volume":"49","author":"Michels","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0132|cit132","unstructured":"Mieler WF PIER: Year 1 FA\/OCT results in a study of ranibizumab (Lucentis\u2122) for CNV due to ARMD European VitreoRetinal Society 2006. Symposium I: Anti-Angiogenesis (Part 1). www.evrs.eu\/2006-evrs-congress-cannes"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0133|cit133","unstructured":"Regillo CD Bressler NM Fine JT Dolan CM Marceau C Chang TS Vision-specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis\u2122) European VitreoRetinal Society 2006. Poster Session. www.evrs.eu\/2006-evrs-congress-cannes\/poster-session-amdanti-angiogenesis"},{"issue":"2","key":"10.1002\/14651858.CD005139.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0135|cit135","unstructured":"Regillo CD Chung CY Wilson L PIER Study Group Ranibizumab in neovascular age-related macular degeneration (AMD): crossover\/rollover treatment effects in PIER study The Macula Society 2008 166"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0136|cit136","first-page":"ARVO E-Abstract","article-title":"Visual acuity gain with ranibizumab therapy: two-year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD","volume":"49","author":"Wolf","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0137|cit137","first-page":"ARVO E-Abstract","article-title":"Intravitreal bevacizumab (Avastin\u00ae) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age-related macular degeneration","volume":"48","author":"Michels","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0138|cit138","first-page":"ARVO E-Abstract","article-title":"Intravitreal bevacizumab (Avastin\u00ae) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial","volume":"49","author":"Prager","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/eye.2008.423","article-title":"Randomised clinical trial of intravitreal Avastin\u00ae vs photodynamic therapy and intravitreal triamcinolone: long-term results","volume":"23","author":"Sacu","year":"2009","journal-title":"Eye"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/bjo.2007.125823","article-title":"Intravitreal bevacizumab (Avastin\u00ae) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study","volume":"92","author":"Weigert","year":"2008","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000478665","article-title":"SAVE-AMD: safety of VEGF inhibitors in age-related macular degeneration","volume":"238","author":"Enseleit","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00508-014-0539-z","article-title":"Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD","volume":"126","author":"Scholler","year":"2014","journal-title":"Wiener Klinische Wochenschrift (Central European Journal of Medicine)"},{"issue":"2","key":"10.1002\/14651858.CD005139.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ajo.2010.04.006","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial","volume":"150","author":"Donahue","year":"2010","journal-title":"American Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ajo.2009.12.039","article-title":"Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions","volume":"149","author":"Messori","year":"2010","journal-title":"American Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD005139.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/eye.2010.147","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial","volume":"24","author":"Subramanian","year":"2010","journal-title":"Eye"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2009.07.009","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial","volume":"148","author":"Subramanian","year":"2009","journal-title":"American Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ajo.2009.12.040","article-title":"Reply","volume":"149","author":"Subramanian","year":"2010","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0148|cit148","unstructured":"Chakravarthy U Efficacy and safety of pegaptanib in age-related macular degeneration: three-year results of the V.I.S.I.O.N. trials The Macula Society 2006 116"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0149|cit149","unstructured":"D'Amico DF Macugen \u00ae in neovascular age-related macular degeneration: exploratory subgroup analyses American Academy of Ophthalmology 2005 261"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0151|cit150","first-page":"ARVO E-abstract","article-title":"VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data","volume":"46","author":"D'Amico","year":"2005","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0150|cit151","first-page":"ARVO E-Abstract","article-title":"VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): safety evaluation from the pivotal Macugen\u00ae (pegaptanib sodium) clinical trials","volume":"45","author":"D'Amico","year":"2004","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0152|cit152","unstructured":"Eyetech Pharmaceuticals Inc Pfizer Inc Pegaptanib sodium injection in the treatment of neovascular age-related macular degeneration www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/2004-4053b1.htm"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0153|cit153","unstructured":"FDA Macugen \u00ae (pegaptanib sodium injection) for the treatment of neovascular age-related macular degeneration www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/2004-4053b1.htm"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0155|cit154","first-page":"ARVO E-abstract","article-title":"VEGF Inhibition Study in Ocular Neovascularization-1 (VISION-1): efficacy results from phase II\/III Macugen\u00ae (pegaptanib sodium) clinical trials","volume":"45","author":"Gragoudas","year":"2004","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"27","key":"10.1002\/14651858.CD005139.pub4-BIB0154|cit155","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/IAE.0b013e3182a487be","article-title":"Retinal vascular abnormalities in neovascular age-related macular degeneration","volume":"34","author":"Jackson","year":"2014","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0157|cit157","unstructured":"Kuppermann BD The V.I.S.I.O.N. Study: results with two years of Macugen \u00ae and outcomes of earlier treatment in early disease American Academy of Ophthalmology 2005 178"},{"issue":"35","key":"10.1002\/14651858.CD005139.pub4-BIB0158|cit158","first-page":"3301","article-title":"Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor - secondary publication","volume":"167","author":"Larsen","year":"2005","journal-title":"Ugeskrift for Laeger"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.eye.6702900","article-title":"Quality of life in patients with age-related macular degeneration: results from the VISION study","volume":"22","author":"Leys","year":"2008","journal-title":"Eye"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.ophtha.2007.02.021","article-title":"Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration","volume":"114","author":"Apte","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0161|cit161","first-page":"ARVO E- Abstrac","article-title":"Four-year safety of pegaptanib sodium in neovascular age-related macular degeneration (AMD): results of the V.I.S.I.O.N. trial","volume":"49","author":"Marcus","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0162|cit162","first-page":"ARVO E-Abstract","article-title":"Safety evaluation of second year treatment of age-related macular degeneration with pegaptanib sodium (Macugen\u00ae): VEGF Inhibition Study in Ocular Neovascularization (VISION)","volume":"46","author":"Mieler","year":"2005","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jclinepi.2006.09.001","article-title":"A randomized trial of pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects","volume":"60","author":"Mills","year":"2007","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0164|cit164","unstructured":"Patel M Mones J Leys A Zlateva G Shah SN Quality of life in patients with age-related macular degeneration: results from the V.I.S.I.O.N. trial European VitreoRetinal Society 2006. Poster Session. www.evrs.eu\/2006-evrs-congress-cannes\/poster-session-amdanti-angiogenesis"},{"issue":"16","key":"10.1002\/14651858.CD005139.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJM200504213521619","article-title":"Pegaptanib and age-related macular degeneration","volume":"352","author":"Rakic","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0166|cit166","unstructured":"Singerman LI Two-year systemic safety of pegaptanib in patients with neovascular age-related macular degeneration: results of the V.I.S.I.O.N. trials The Macula Society 2006 120"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/bjo.2007.132597","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial","volume":"92","author":"Singerman","year":"2008","journal-title":"British Journal of Ophthalmology"},{"issue":"35","key":"10.1002\/14651858.CD005139.pub4-BIB0168|cit168","first-page":"3267","article-title":"Antiangiogenesis therapy of age-related macular degeneration","volume":"167","author":"Sjolie","year":"2005","journal-title":"Ugeskrift for Laeger"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0169|cit169","doi-asserted-by":"crossref","unstructured":"VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group Chakravarthy U Adamis AP Cunningham ET Jr Goldbaum M Guyer DR Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration Ophthalmology 2006 1508","DOI":"10.1016\/j.ophtha.2006.02.064"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0170|cit170","first-page":"1001","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials","volume":"113","author":"D'Amico","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0171|cit171","first-page":"ARVO E-Abstract","article-title":"Quality of life in patients with age-related macular degeneration: results from the VISION study","volume":"47","author":"Zlateva","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0172|cit172","unstructured":"Safety and efficacy of oral PTK787 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) (ADVANCE) ClinicalTrials.gov NCT00138632"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0173|cit173","unstructured":"Photodynamic therapy combined with bevacizumab vs bevacizumab alone for neovascular age-related macular degeneration (ARMAST) ClinicalTrials.gov NCT0069592"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/archopht.125.10.1357","article-title":"Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration","volume":"125","author":"Bashshur","year":"2007","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0175|cit175","first-page":"ARVO E-Abstract","article-title":"Systemic bevacizumab therapy for exudative neovascular age-related macular degeneration (BEAT-AMD-Study)","volume":"49","author":"Schmid-Kubista","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD005139.pub4-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/bjo.2008.144410","article-title":"Systemic bevacizumab (Avastin\u00ae) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study","volume":"93","author":"Schmid-Kubista","year":"2009","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0177|cit177","first-page":"821","article-title":"Efficacy of RTH258 (ESBA1008), an anti-VEGF agent, applied by microvolume injection or infusion in subjects with neovascular AMD","volume":"56 (7)","author":"Berger","year":"2015","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/IAE.0000000000000334","article-title":"Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications","volume":"35","author":"Blaha","year":"2015","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0179|cit179","first-page":"ARVO E-Abstract","article-title":"The relevance of measuring central retinal thickness during intra-vitreal therapy with ranibizumab: analyzing a multi-center clinical trial","volume":"49","author":"Bolz","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0180|cit180","first-page":"4419","article-title":"CNV lesion characteristics as a predictor of visual outcome in wet AMD patients receiving combination therapy of intravitreal anti-VEGF therapy and topical Squalamine lactate ophthalmic solution","volume":"57(12)","author":"Brown","year":"2016","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"11","key":"10.1002\/14651858.CD005139.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00417-008-0890-8","article-title":"Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration","volume":"246","author":"Cohen","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD005139.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.2009.159343","article-title":"Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration","volume":"94","author":"Costagliola","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ophtha.2014.09.036","article-title":"Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration","volume":"122","author":"Csaky","year":"2015","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.clinthera.2007.09.001","article-title":"Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada","volume":"29","author":"Earnshaw","year":"2007","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0185|cit185","first-page":"1517","article-title":"Randomized comparison of anterior chamber inflammatory activity in eyes treated with intravitreal aflibercept or ranibizumab","volume":"56(7)","author":"Eibenberger","year":"2015","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0186|cit186","first-page":"4434","article-title":"A phase 2 study (EMERGE) evaluating repeated intravitreal administration of ICON-1 in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)","volume":"57(12)","author":"Christmas","year":"2016","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0187|cit187","unstructured":"NCT02358889 Study evaluating intravitreal hl-con1 TM in patients with ehoroidal neovascularization secondary to age-related macular degeneration (EMERGE) ClinicalTrials.gov (accessed 24 August 2018)"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/23258160-20180501-07","article-title":"A phase I, open-label, dose-excalation trial to investigate safety and tolerability of single intravitreous injections of ICON-1 targeting tissue factor in wet AMD","volume":"49","author":"Wells","year":"2018","journal-title":"Ophthalmic Surgery, Lasers and Imaging Retina"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0189|cit189","first-page":"245","article-title":"Results of comparison in use to alternative therapy methods for subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"17","author":"Erdokur","year":"2009","journal-title":"Retina-Vitreus"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0191|cit190","first-page":"ARVO E-Abstract","article-title":"The safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration: 12-month results from the phase I\/II EXTEND-I study","volume":"49","author":"Tano","year":"2008","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0190|cit191","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1755-3768.2009.01843.x","article-title":"EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration","volume":"88","author":"Tano","year":"2010","journal-title":"Acta Ophthalmologica"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0161-6420(03)00085-X","article-title":"Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results","volume":"110","author":"Eyetech Study Group","year":"2003","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/IAE.0b013e3180654240","article-title":"Standardized visual acuity results associated with primary versus secondary bevacizumab (Avastin\u00ae) treatment for choroidal neovascularization in age-related macular degeneration","volume":"27","author":"Falkenstein","year":"2007","journal-title":"Retina"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ophtha.2008.07.018","article-title":"Computerized model of cost-utility analysis for treatment of age-related macular degeneration","volume":"115","author":"Fletcher","year":"2008","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ajo.2007.12.029","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results","volume":"145","author":"Antoszyk","year":"2008","journal-title":"American Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD005139.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/archopht.124.11.1532","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study","volume":"124","author":"Heier","year":"2006","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0197|cit197","unstructured":"Heier JS FOCUS Study Group Intravitreal ranibizumab with verteporfin photodynamic therapy for neovascular age-related macular degeneration: year one results Program and abstracts of the American Society of Retina Specialists 23rd Annual Meeting; 2005 July 16-20; Montreal 2005"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0198|cit198","unstructured":"NCT02036723 Multicentre double blind randomized clinical study evaluating the efficacy and safety of BCD-021 (CJSC BIOCAD, Russia) and Lucentis \u00ae (Novartis Pharmaceuticals Canada Inc.) in patients with neovascular wet age-related macular degeneration (GALATIR) clinicaltrials.gov\/show\/NCT02036723"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0199|cit199","first-page":"4985","article-title":"A proof of concept study of intravitreal (IVT) LFG316 in patients with neovascular age related macular degeneration (NAMD)","volume":"57(12)","author":"Gallemore","year":"2016","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD005139.pub4-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00347-007-1547-4","article-title":"Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration","volume":"104","author":"Hahn","year":"2007","journal-title":"Der Ophthalmologe"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/IAE.0b013e3181bcedbe","article-title":"Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography","volume":"30","author":"Hatta","year":"2010","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0202|cit202","first-page":"5018","article-title":"A 2-year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age-related macular degeneration: testing an alternative treatment regimen","volume":"57(12)","author":"Dugel","year":"2016","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"642. e1-4","DOI":"10.1016\/j.ophtha.2005.10.052","article-title":"Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I\/II multicenter, controlled, multidose study","volume":"113","author":"Heier","year":"2006","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.clinthera.2008.12.025","article-title":"Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration","volume":"30","author":"Hernandez-Pastor","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0205|cit205","first-page":"467","article-title":"Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration","volume":"248","author":"Hernandez-Pastor","year":"2010","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1524-4733.2007.00283.x","article-title":"Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity","volume":"11","author":"Javitt","year":"2008","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0208|cit208","first-page":"4965","article-title":"VEGF Plasma levels after intravitreal injection of aflibercept and ranibizumab","volume":"55(13)","author":"Kralinger","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/IAE.0b013e3181b32c45","article-title":"Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial","volume":"29","author":"Lai","year":"2009","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ophtha.2007.03.006","article-title":"Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration","volume":"114","author":"Lazic","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"676049","DOI":"10.1155\/2013\/676049","article-title":"Predictors of visual response to intravitreal bevacizumab for treatment of neovascular age-related macular degeneration","volume":"2013","author":"Fang","year":"2013","journal-title":"Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.ophtha.2012.05.016","article-title":"Bevacizumab for neovascular age-related macular degeneration in China","volume":"119","author":"Li","year":"2012","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD005139.pub4-BIB0213|cit213","first-page":"169","article-title":"Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients","volume":"6","author":"Li","year":"2013","journal-title":"International Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0214|cit214","first-page":"337","article-title":"Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib","volume":"108","author":"Matthe","year":"2011","journal-title":"Der Ophthalmologe"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0215|cit215","first-page":"85","article-title":"Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat neovascular age-related macular degeneration: interim analysis","volume":"100","author":"Pulido","year":"2002","journal-title":"Transactions of the American Ophthalmological Society"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0008-4182(05)80076-6","article-title":"Rheopheresis for age-related macular degeneration: clinical results and putative mechanism of action","volume":"40","author":"Pulido","year":"2005","journal-title":"Canadian Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/IAE.0b013e318198148e","article-title":"Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin\u00ae) for treatment of CNV associated with AMD","volume":"29","author":"Modarres","year":"2009","journal-title":"Retina"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0218|cit218","unstructured":"NCT00087763 A phase II prospective, randomized, double-masked, sham-controlled, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on foveal thickening in patients with exudative subfoveal age-related macular degeneration (AMD) clinicaltrials.gov\/show\/NCT00087763"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0220|cit220","first-page":"319","article-title":"Results from a phase I\/II clinical trial on anti-vascular endothelial growth factor gene therapy in patients with exudative age-related macular degeneration","volume":"15(8-9)","author":"Lai","year":"2013","journal-title":"Journal of Gene Medicine"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0221|cit221","first-page":"315","article-title":"Optical coherence tomography profiles, visual acuity and ranibizumab usage during 3-year follow-up in a rAAV.sFLT-1 gene therapy clinical trial for wet age-related macular degeneration","volume":"25","author":"Lai","year":"2017","journal-title":"Molecular therapy. Conference: 20th Annual Meeting of the American Society of Gene and Cell Therapy, ASGCT 2017. United States"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0222|cit222","first-page":"526","article-title":"Association of serum neutralizing antibodies with safety and efficacy outcomes in a Phase 2a trial of rAAV.sFlt- 1 in the treatment of wet AMD","volume":"57(12)","author":"Rakoczy","year":"2016","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0225|cit225","doi-asserted-by":"crossref","unstructured":"Neubauer AS Holz FG Schrader W Back EI Kuhn T Hirneiss C Cost-utility analysis of ranibizumab (Lucentis \u00ae ) in neovascular macular degeneration Klinische Monatsblatter fur Augenheilkunde 2007 727 32","DOI":"10.1055\/s-2007-963470"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ophtha.2006.05.055","article-title":"A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration","volume":"113","author":"Nguyen","year":"2006","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"CR374","DOI":"10.12659\/MSM.882907","article-title":"A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration","volume":"18","author":"Nowak","year":"2012","journal-title":"Medical Science Monitor"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0228|cit228","first-page":"4939","article-title":"Efficacy and cost-effectiveness of anti-VEGF treatments for age-related macular degeneration (AMD)","volume":"55(13)","author":"Nunes","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0229|cit229","first-page":"4801","article-title":"OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single chain anti-VEGF antibody fragment, in patients with neovascular AMD","volume":"56(7)","author":"Singerman","year":"2015","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD005139.pub4-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/archophthalmol.2011.2617","article-title":"Intravitreal bevacizumab in advanced-stage neovascular age-related macular degeneration with visual acuity lower than 20\/200","volume":"130","author":"Parodi","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/bjophthalmol-2011-301444","article-title":"Treating early choroidal neovascularisation with pegaptanib sodium in patients with neovascular age-related macular degeneration: findings of the PERSPECTIVES study","volume":"96","author":"Chakravarthy","year":"2012","journal-title":"British Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study","volume":"148","author":"Lalwani","year":"2009","journal-title":"American Journal of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/bjo.2007.116616","article-title":"Ranibizumab (Lucentis\u00ae) versus bevacizumab (Avastin\u00ae): modelling cost effectiveness","volume":"91","author":"Raftery","year":"2007","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0234|cit234","unstructured":"NCT01319188 Ranibizumab for age-related macular degeneration and the risk of arterial thromboembolic events (RATE) clinicaltrials.gov\/show\/NCT01319188"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0235|cit235","first-page":"29","article-title":"Comparison of ranibizumab and aflibercept in patients with neovascular age-related macular degeneration treated following a 'treat and extend' protocol: efficacy variables from the pre-specified 12-month interim analysis of the rival study","volume":"45","author":"Gillies","year":"2017","journal-title":"Clinical and Experimental Ophthalmology. Conference: 49th Annual Scientific Congress of the Royal Australian and New Zealand College of Ophthalmologists. Australia"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2009.05.024","article-title":"A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration","volume":"116","author":"Boyer","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0237|cit237","unstructured":"Reichel E Francom S Rubio R Ranibizumab (Lucentis \u00ae ) safety in previously treated and newly diagnosed patients with neovascular age-related macular degeneration (AMD): the SAILOR study The Macula Society 2008 168"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/02713683.2011.597536","article-title":"Comparing treatment of neovascular age-related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono-therapy - a pilot study","volume":"36","author":"Schmid-Kubista","year":"2011","journal-title":"Current Eye Research"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/eye.2016.305","article-title":"Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration","volume":"31","author":"Sengul","year":"2017","journal-title":"Eye (London, England)"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/jop.2016.0071","article-title":"Intravitreal aflibercept versus photodynamic therapy in Chinese patients with neovascular age-related macular degeneration: outcomes of the sight study","volume":"33","author":"Li","year":"2017","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0241|cit241","first-page":"E-Abstract 1817","article-title":"Combination therapy with verteporfin PDT and ranibizumab for subfoveal choroidal neovascularization due to AMD","volume":"48","author":"Slakter","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"8","key":"10.1002\/14651858.CD005139.pub4-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1167\/iovs.08-3225","article-title":"Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials","volume":"50","author":"Su\u00f1er","year":"2009","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD005139.pub4-BIB0243|cit243","first-page":"590","article-title":"Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration","volume":"112","author":"Tano","year":"2008","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/eye.2010.84","article-title":"A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration","volume":"24","author":"Vallance","year":"2010","journal-title":"Eye"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0245|cit245","first-page":"E-Abstract 5232","article-title":"VERITAS - The rationale and design of a combination therapy trial for wet AMD","volume":"47","author":"Mieler","year":"2006","journal-title":"Investigative Ophthalmology and Visual Science"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0246|cit246","unstructured":"Marcus DM Long-term follow-up of intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD) in an open-label extension of the VIEW1 study Investigative Ophthalmology and Visual Science 2014 3943"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/bjo.2007.125823","article-title":"Intravitreal bevacizumab (Avastin) versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomized controlled clinical trial","volume":"92","author":"Weigert","year":"2008","journal-title":"British Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2165\/00019053-200725100-00005","article-title":"Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK","volume":"25","author":"Wolowacz","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/bjophthalmol-2012-302451","article-title":"Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema","volume":"97","author":"Zehetner","year":"2013","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0251|cit251","unstructured":"NCT00559715 Prevention of vision loss in patients with age-related macular degeneration (AMD) by intravitreal injection of bevacizumab and ranibizumab (VIBERA) clinicaltrials.gov\/show\/NCT00559715"},{"issue":"22","key":"10.1002\/14651858.CD005139.pub4-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0253|cit253","first-page":"1414","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8","volume":"119","author":"Age-Related Eye Disease Study Research Group","year":"2001","journal-title":"Archives of Ophthalmology"},{"issue":"19","key":"10.1002\/14651858.CD005139.pub4-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2013.4997","article-title":"Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial","volume":"309","author":"Age-Related Eye Disease Study 2 Research Group","year":"2013","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1001\/archopht.125.10.1396","article-title":"C-reactive protein level and risk of aging macula disorder: the Rotterdam study","volume":"125","author":"Boekhoorn","year":"2007","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bjophthalmol-2013-304033","article-title":"Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010","volume":"98","author":"Bourne","year":"2014","journal-title":"British Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ophtha.2007.08.033","article-title":"A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration","volume":"115","author":"Brown","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2458-6-58","article-title":"Leading causes of certification for blindness and partial sight in England & Wales","volume":"6","author":"Bunce","year":"2006","journal-title":"BMC Public Health"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0259|cit259","first-page":"1149","article-title":"Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting","volume":"6","author":"Carneiro","year":"2012","journal-title":"Clinical Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0260|cit260","unstructured":"Centers for Medicare and Medicaid Services Billing and coding information regarding uses, including off-label uses, of bevacizumab and ranibizumab, for the treatment of ophthalmological diseases. Document ID A49034 www.cms.gov\/medicare-coverage-database"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"g2006","DOI":"10.1136\/bmj.g2006","article-title":"Roche and Novartis colluded over wet AMD drugs, says Italian regulator","volume":"348","author":"Cohen","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0263|cit263","unstructured":"de Juan E Laganovska G Loewenstein A Alster Y Erickson S First in-human results of a refillable drug delivery implant providing sustained release of ranibizumab in patients with neovascular AMD Macula Society 2013 136 7"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archopht.125.1.49","article-title":"Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration","volume":"125","author":"Deangelis","year":"2007","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0265|cit265","unstructured":"Deeks JJ Higgins JP Altman DG editor(s) Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0266|cit266","unstructured":"Eyetech Pharmaceuticals Inc Pfizer Inc Pegaptanib sodium injection in the treatment of neovascular age-related macular degeneration; and FDA. Macugen \u00ae (pegaptanib sodium injection) for the treatment of neovascular age-related macular degeneration www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/2004-4053b1.htm"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0267|cit267","unstructured":"Eyetech Pharmaceuticals Inc Pfizer Inc Pegaptanib sodium injection in the treatment of neovascular age-related macular degeneration; and FDA. Macugen \u00ae (pegaptanib sodium injection) for the treatment of neovascular age-related macular degeneration www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/2004-4053b1.htm"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.1941.00870100042005","article-title":"Prevalence of age-related macular degeneration in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/bjo.67.4.209","article-title":"Common causes of blindness and visual handicap in the west of Scotland","volume":"67","author":"Ghafour","year":"1983","journal-title":"British Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ophtha.2013.09.050","article-title":"Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD005139.pub4-BIB0271|cit271","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0272|cit272","unstructured":"GRADE Working Group, McMaster University GRADEpro 2014"},{"issue":"27","key":"10.1002\/14651858.CD005139.pub4-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.survophthal.2006.05.001","article-title":"The genetics of age-related macular degeneration: a review of progress to date","volume":"51","author":"Haddad","year":"2006","journal-title":"Survey of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0275|cit275","unstructured":"Higgins JP Altman DG Sterne JAC editor(s) Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","article-title":"Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme","volume":"97","author":"Holz","year":"2013","journal-title":"British Journal of Ophthalmology"},{"issue":"Pt 2","key":"10.1002\/14651858.CD005139.pub4-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/eye.1987.53","article-title":"Epidemiology of eye disease in the elderly","volume":"1","author":"Hyman","year":"1987","journal-title":"Eye"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2008.08.012","article-title":"Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"115","author":"Ip","year":"2008","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/archopht.126.1.115","article-title":"Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration","volume":"126","author":"Klein","year":"2008","journal-title":"Archives of Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0280|cit280","first-page":"1929","article-title":"Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor","volume":"37","author":"Kvanta","year":"1996","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"Suppl","key":"10.1002\/14651858.CD005139.pub4-BIB0281|cit281","first-page":"335","article-title":"The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975","volume":"24","author":"Leibowitz","year":"1980","journal-title":"Survey of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0282|cit282","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012208","article-title":"Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","author":"Li","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD005139.pub4-BIB0283|cit283","first-page":"855","article-title":"Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes","volume":"37","author":"Lopez","year":"1996","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/archopht.120.10.1357","article-title":"Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study","volume":"120","author":"Mitchell","year":"2002","journal-title":"Archives of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD005139.pub4-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1185\/03007995.2011.585394","article-title":"A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab","volume":"27","author":"Mitchell","year":"2011","journal-title":"Current Medical Research and Opinion"},{"issue":"9","key":"10.1002\/14651858.CD005139.pub4-BIB0286|cit286","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011230.pub2","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","author":"Moja","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD005139.pub4-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archopht.1991.01080080069030","article-title":"Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials","volume":"109","author":"Macular Photocoagulation Study Group","year":"1991","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/bjo.87.3.312","article-title":"How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?","volume":"87","author":"Owen","year":"2003","journal-title":"British Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/ICU.0000000000000050","article-title":"Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration","volume":"25","author":"Rasmussen","year":"2014","journal-title":"Current Opinion in Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0290|cit290","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"11","key":"10.1002\/14651858.CD005139.pub4-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD005139.pub4-BIB0292|cit292","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011346.pub2","article-title":"Aflibercept for neovascular age-related macular degeneration","author":"Sarwar","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/archopht.125.1.55","article-title":"A prospective study of 2 major age-related macular degeneration susceptibility alleles and interactions with modifiable risk factors","volume":"125","author":"Schaumberg","year":"2007","journal-title":"Archives of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/ICU.0b013e3283386783","article-title":"Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review","volume":"21","author":"Schmucker","year":"2010","journal-title":"Current Opinion in Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD005139.pub4-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"e42701","DOI":"10.1371\/journal.pone.0042701","article-title":"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus gold standard","volume":"7","author":"Schmucker","year":"2012","journal-title":"PloS One"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000094141","article-title":"CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration","volume":"61","author":"Seddon","year":"2006","journal-title":"Human Heredity"},{"issue":"12","key":"10.1002\/14651858.CD005139.pub4-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1001\/archopht.1996.01100140716016","article-title":"Smoking and age-related maculopathy. The Blue Mountains Eye Study","volume":"114","author":"Smith","year":"1996","journal-title":"Archives of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD005139.pub4-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archopht.125.10.1323","article-title":"Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group","volume":"125","author":"Solomon","year":"2007","journal-title":"Archives of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD005139.pub4-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ophtha.2013.10.037","article-title":"Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration","volume":"121","author":"Stein","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0300|cit300","article-title":"Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older","volume-title":"Prevent Blindness","author":"Tielsch","year":"1994"},{"issue":"6","key":"10.1002\/14651858.CD005139.pub4-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/archopht.120.6.731","article-title":"Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration","volume":"120","author":"Ting","year":"2002","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD005139.pub4-BIB0302|cit302","first-page":"75","article-title":"Features of age-related macular degeneration on optical coherence tomography","volume":"281","author":"Kerckhoven","year":"2001","journal-title":"Bulletin de la Societe Belge d'Ophtalmologie"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0303|cit303","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004763.pub2","article-title":"Laser photocoagulation for neovascular age-related macular degeneration","author":"Virgili","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD005139.pub4-BIB0304|cit304","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002030.pub2","article-title":"Photodynamic therapy for neovascular age-related macular degeneration","author":"Wormald","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0305|cit305","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration","author":"Krzystolik","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD005139.pub4-BIB0306|cit306","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub3","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Solomon","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD005139.pub4-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ophtha.2015.09.002","article-title":"Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a Cochrane systematic review","volume":"123","author":"Solomon","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD005139.pub4-BIB0308|cit308","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub2","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration","author":"Vedula","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005139.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T10:29:53Z","timestamp":1638440993000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005139.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":308,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005139.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]}}}